News Releases
Mar 25, 2021
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
Additional Formats
Mar 17, 2021
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
Additional Formats
Feb 24, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
Additional Formats
Feb 18, 2021
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Additional Formats
Feb 17, 2021
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
Additional Formats
Feb 01, 2021
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
Additional Formats
Jan 06, 2021
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
Additional Formats
Jan 05, 2021
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Additional Formats